Unique ID issued by UMIN | UMIN000033832 |
---|---|
Receipt number | R000038587 |
Scientific Title | Investigation of promoting osteogenesis by intake of vitamin K2-rich Natto |
Date of disclosure of the study information | 2018/08/21 |
Last modified on | 2018/08/21 11:06:23 |
Investigation of promoting osteogenesis by intake of vitamin K2-rich Natto
Investigation of promoting osteogenesis by intake of vitamin K2-rich Natto
Investigation of promoting osteogenesis by intake of vitamin K2-rich Natto
Investigation of promoting osteogenesis by intake of vitamin K2-rich Natto
Japan |
Healthy Adult
Adult |
Others
NO
Promoting osteogenesis and improving bone metabolism function when feeding Natto for 6 weeks
Efficacy
Blood (osteocalcin)
Urine (Type I collagen cross-linked N- telopeptide),
Urine (deoxypyridinoline),
Blood (vitamin K2)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Food |
Natto
40 | years-old | <= |
64 | years-old | >= |
Female
Postmenopausal women of ages 40 to 64 years old
1. Persons who has liver disease, renal disease, digestive organ disease, heart trouble, peripheral vascular disorder, a person with a history of the past that may have an influence on other final examination results or person with a history of the operation
2. Person who take warfarin
3. Persons who liver function and renal function test values show abnormalities
4. Currently, those with a disorder under treatment
5. Persons who have food or drug allergy
6. Person who suffer from anemia
7. Persons who do intense sports or are on a diet
8. Persons who can't stop using functional foods (including Food for Specified Health Uses or Foods with Function Claims) and/or Specified quasi-drugs during the current study periods
9. Persons who are taking healthfoods, quasi medical items, medicines (including OTC, prescription medicine) containing ingredients contained in the test food
10. Persons who consume excess alcohol or can not abstinence from the day before the test until the day
11. Persons who are pregnant, or persons who are planning to become pregnant or breastfeeding during the study period
12. Persons who are participating in the other study or planning to participate during the study period
13. Persons who judged inappropriate by the study responsible doctor for other reasons
15
1st name | |
Middle name | |
Last name | Naoki Miura |
Miura Clinic, Medical Corporation Kanonkai
Internal Medicine
9F Higashitenma Bldg.,1-7-17 Higashitenma, Kita-ku, Osaka-shi, Osaka, Japan
06-6135-5200
info@miura-cl.jp
1st name | |
Middle name | |
Last name | Makoto Terashima |
Oneness Support Co., Ltd.
Clinical trial Division
9F Higashitenma Bldg.,1-7-17 Higashitenma, Kita-ku, Osaka-shi, Osaka, Japan
06-4801-8917
mterashima@miura-cl.jp
Takanofoods Co., Ltd.
Takanofoods Co., Ltd.
Profit organization
Miura Clinic, Medical Corporation Kanonkai
Oneness Support Co., Ltd.
NO
2018 | Year | 08 | Month | 21 | Day |
Unpublished
Preinitiation
2018 | Year | 08 | Month | 18 | Day |
2018 | Year | 08 | Month | 23 | Day |
2018 | Year | 08 | Month | 21 | Day |
2018 | Year | 08 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038587